<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Idursulfase: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Idursulfase: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Idursulfase: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8971" href="/d/html/8971.html" rel="external">see "Idursulfase: Drug information"</a> and <a class="drug drug_patient" data-topicid="11767" href="/d/html/11767.html" rel="external">see "Idursulfase: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708563"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Life-threatening anaphylactic reactions have occurred in some patients during and up to 24 hours after idursulfase infusions. Anaphylaxis, presenting as respiratory distress, hypoxia, hypotension, urticaria, and/or angioedema of throat or tongue, has been reported to occur during and after idursulfase infusions, regardless of duration of the course of treatment. Closely observe patients during and after administration and be prepared to manage anaphylaxis. Inform patients of the signs and symptoms of anaphylaxis and have them seek immediate medical care should symptoms occur. Patients with compromised respiratory function or acute respiratory disease may be at risk of serious acute exacerbation of their respiratory compromise due to hypersensitivity reactions, and require additional monitoring.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F3151893"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Elaprase</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868805"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Elaprase</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F6915106"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Enzyme</span></li></ul></div>
<div class="block dop drugH1Div" id="F3151942"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="085a214b-c08e-469e-b3f6-8d8c45669afb">Mucopolysaccharidosis type II</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mucopolysaccharidosis type II (MPS II, Hunter syndrome): Note:</b> Current consensus opinion recommends initiation of therapy as early as possible following diagnosis (Scarpa 2011):</p>
<p style="text-indent:-2em;margin-left:4em;">Children 16 months to &lt;5 years: Limited data available: IV: 0.5 mg/kg once weekly (Muenzer 2011; Scarpa 2011). A small, open-labeled evaluation of the safety and efficacy of 53 weeks of therapy in 28 pediatric patients ≤5 years of age showed enzyme replacement with idursulfase reduced splenic volume similar to older pediatric patients but data did not support improvement in other disease-related symptoms (which were undefined) or long-term clinical outcomes (which were undefined) (manufacturer's labeling). Proving clinical benefit of therapy for disease-related symptoms in this population is challenging due to age-related compliance with evaluation techniques (eg, walking capacity evaluations, FEV) (Muenzer 2011). A larger observation trial (n=124) of patients &lt;6 years (including infants) showed weekly administration of idursulfase produced a significant decrease in hepatic volume and a reduction in urine glycosaminoglycans (GAG) levels similar to that in older pediatric patients (Muenzer 2011).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥5 years and Adolescents: IV: 0.5 mg/kg once weekly.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51113691"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51113692"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F3151943"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8971" href="/d/html/8971.html" rel="external">see "Idursulfase: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b7590e9c-025f-4ffd-adda-54151e6db764">Mucopolysaccharidosis II</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;">
<b>Mucopolysaccharidosis II (Hunter syndrome):</b>
<b>IV:</b> 0.5 mg/kg once weekly.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990530"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50987841"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F3151927"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing (7% to 16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (28%), fatigue (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (19% to 32%), pruritus (25%), urticaria (16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Vomiting (5% to 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (57% to 69%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (neutralizing: 41% to 79%), development of IgG antibodies (51% to 68%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Musculoskeletal pain (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otitis (children: 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonia (children: 18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (9% to 36%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Tachycardia (9%), hypotension (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Chills (9%), dizziness (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (9%), nausea (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (9%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia, pulmonary embolism</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, cyanosis, loss of consciousness, respiratory distress, respiratory failure, seizure</p></div>
<div class="block coi drugH1Div" id="F3151923"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">There are no contraindications listed in the manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<i>Canadian labeling:</i> Hypersensitivity to idursulfase or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F3151924"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity/anaphylactoid reactions: <b>[US Boxed Warning]: Serious hypersensitivity reactions, including fatal life-threatening anaphylactic reactions, have been reported during and within 24 hours after infusion. Anaphylaxis may present as respiratory distress, hypoxia, hypotension, urticaria, and/or tongue/throat angioedema. Monitor closely during and after infusion. Appropriate medical support should be readily available. Patients with compromised respiratory function or acute respiratory disease are at risk of respiratory disease exacerbation due to hypersensitivity; additional monitoring may be required.</b> Discontinue immediately if anaphylactic or acute reaction occurs. Patients experiencing initial severe or refractory reactions may need prolonged monitoring. Antihistamines, corticosteroids and/or decreased infusion rates may be used to manage subsequent infusions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Antibody formation: Development of anti-idursulfase IgG antibodies has been reported in 51% of patients; may increase incidence of hypersensitivity reactions.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acute febrile/respiratory illness: Hypersensitivity reactions may occur. Use caution and consider delaying treatment in patients with compromised respiratory function or acute febrile or respiratory illness; may be at increased risk for life-threatening complications from hypersensitivity reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Fluid overload: Use with caution in patients at risk for fluid overload or in conditions where fluid restriction is indicated (eg, acute underlying respiratory illness, compromised cardiac and/or respiratory function); conditions may be exacerbated during infusion. Extended observation may be necessary for some patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Genetic mutations: Use with caution in patients with severe genetic mutations (eg, complete gene deletion, large gene rearrangement, nonsense, frameshift or splice site mutations); may increase risk of hypersensitivity reactions, serious adverse reactions, and antibody development.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Registry: Patients and healthcare providers are encouraged to participate in the Hunter Outcome Survey, intended to monitor disease progression, patient outcomes, and long-term effects of therapy. For more information, refer to www.elaprase.com or call OnePath<sup>sm</sup> at 1-866-888-0660.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878707"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">When compared to pediatric patients &gt;7 years, the patients ≤7 years of age were shown to have more frequent development of anti-idursulfase IgG antibodies (68% vs 51%) and neutralizing antibodies (79% vs 41%). In patients &lt;5 years of age, an association between the presence of antibodies and reduced systemic idursulfase exposure has been observed; this has not been reported in older pediatric patients (≥5 years of age). Younger pediatric patients have also been shown to develop neutralizing antibodies earlier in therapy (at week 9 vs 27) and at higher titers.</p></div>
<div class="block foc drugH1Div" id="F3151950"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Elaprase: 6 mg/3 mL (3 mL)</p></div>
<div class="block geq drugH1Div" id="F3151894"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16322949"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Elaprase Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6 mg/3 mL (per mL): $1,254.33</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868806"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Elaprase: 6 mg/3 mL (3 mL)</p></div>
<div class="block admp drugH1Div" id="F52614213"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;text-align:justify;display:inline">IV: Administer using an infusion set containing a 0.2 micron low protein-binding inline filter. Infuse at an initial rate of 8 mL/hour for the first 15 minutes. If tolerated, may increase rate by 8 mL/hour increments every 15 minutes up to maximum infusion rate of 100 mL/hour. Rate may be decreased, temporarily stopped, or discontinued based on tolerance. Initial infusion should be over 3 hours; if tolerated, subsequent infusions may be gradually reduced to a 1-hour infusion. Total infusion time should not exceed 8 hours. <b>Note:</b> For subsequent doses, current guidelines suggest that shortened infusion time of 1 hour is not desirable and increased the risk of infusion-related reaction; extra precautions should be used (Scarpa 2011).</p></div>
<div class="block adm drugH1Div" id="F3151945"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: Administer using an infusion set containing a 0.2 micron low protein-binding inline filter. Infuse at an initial rate of 8 mL/hour for the first 15 minutes. If tolerated, may increase rate by 8 mL/hour increments every 15 minutes; maximum infusion rate of up to 100 mL/hour. Rate may be decreased, temporarily stopped, or discontinued based on tolerance. Initial infusion should be over 3 hours; if tolerated, subsequent infusions may be gradually reduced to a 1-hour infusion. Total infusion time should not exceed 8 hours.</p></div>
<div class="block sts drugH1Div" id="F3151933"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store vials under refrigeration at 2°C to 8°C (36°F to 46°F). Protect from light, do not freeze or shake. Should be used immediately after dilution in NS. However, solution for infusion may be stored under refrigeration for up to 24 hours.</p></div>
<div class="block usep drugH1Div" id="F53570076"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Replacement therapy in mucopolysaccharidosis II (MPS II, Hunter syndrome) (FDA approved in ages ≥5 years and adults).</p></div>
<div class="block mst drugH1Div" id="F3151890"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Elaprase may be confused with Elspar</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299508"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6220952"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F3151921"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were not observed in animal reproduction studies.</p></div>
<div class="block mopp drugH1Div" id="F53570077"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for infusion-related and hypersensitivity reactions; pulmonary function, oxygen saturation; blood pressure.</p></div>
<div class="block pha drugH1Div" id="F3151937"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;text-align:justify;display:inline">Idursulfase is a recombinant form of iduronate-2-sulfatase, an enzyme needed to hydrolyze the mucopolysaccharides dermatan sulfate and heparan sulfate in various cells. Accumulation of these polysaccharides can lead to various manifestations of disease, including physical changes, CNS involvement, cardiac, respiratory, and mobility dysfunction. Replacement of this enzyme has been shown to improve walking capacity in patients with a deficiency. </p></div>
<div class="block phk drugH1Div" id="F3151939"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Varies dependent upon age and presence of antibodies (particularly patients &lt;7.5 years): V<sub>ss</sub>:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 16 months to &lt;7.5 years: Week 1: 394 ± 423 mL/kg; Week 27: Antibody negative: 272 ± 112 mL/kg; antibody positive: 829 ± 636 mL/kg</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥7.5 years, Adolescents, and Adults &lt;27 years: Mean range: 213 to 254 mL/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Varies dependent upon age and presence of antibodies (particularly patients &lt;7.5 years)</p>
<p style="text-indent:-2em;margin-left:4em;">Children 16 months to &lt;7.5 years: Week 1: 160 ± 69 minutes; Week 27: Antibody negative: 134 ± 19 minutes; antibody positive: 84 ± 46 minutes</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥7.5 years, Adolescents, and Adults &lt;27 years: Mean range: 44 to 48 minutes</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5378699"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Elaprase</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Elaprase (idursulfase) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals USA Inc: September 2021.</div>
</li>
<li>
<div class="reference">
                  Elaprase (idursulfase) [product monograph]. Toronto, Ontario, Canada: Takeda Canada Inc; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21150784">
<a name="21150784"></a>Muenzer J, Beck M, Eng CM, et al, “Long-Term, Open-Labeled Extension Study of Idursulfase in the Treatment of Hunter Syndrome,” <i>Genet Med</i>, 2011, 13(2):95-101.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/idursulfase-pediatric-drug-information/abstract-text/21150784/pubmed" id="21150784" target="_blank">21150784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21233716">
<a name="21233716"></a>Muenzer J, Beck M, Giugliani R, et al. Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey. <i>Genet Med</i>. 2011;13(2):102-109.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/idursulfase-pediatric-drug-information/abstract-text/21233716/pubmed" id="21233716" target="_blank">21233716</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16912578">
<a name="16912578"></a>Muenzer J, Wraith JE, Beck M, wet al, “A Phase II/III Clinical Study of Enzyme Replacement Therapy With Idursulfase in Mucopolysaccharidosis II (Hunter Syndrome),” <i>Genet Med</i>, 2006, 8(8):465-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/idursulfase-pediatric-drug-information/abstract-text/16912578/pubmed" id="16912578" target="_blank">16912578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22059643">
<a name="22059643"></a>Scarpa M, Almássy Z, Beck M, et al. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. <i>Orphanet J Rare Dis</i>. 2011;6:72<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/idursulfase-pediatric-drug-information/abstract-text/22059643/pubmed" id="22059643" target="_blank">22059643</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 100321 Version 69.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
